Study 6

TITLE

[Clinical experience with Diane-35, currently the lowest dose antiandrogenic hormonal ovulation inhibitor, in mild to moderative androgenization in the female]. Klinische Erfahrungen mit Diane-35, dem zur Zeit niedrigst dosierten antiandrogen wirkenden hormonalen Ovulationshemmer, bei leichten bis mittelstarken Androgenisierungserscheinungen der Frau.

AUTHOR
Kaiser E

SOURCE
Geburtshilfe Frauenheilkd 1986 Oct; 46 (10): 738-42

LANGUAGE OF PUBLICATION
German

ABSTRACT
Low-dose hormonal contraceptives with specifically reduced estrogen are now the drug of choice for the prevention of internal risks. The antiandrogenic hormonal contraceptives have also had to be adapted to this situation. In a study involving 144 women, most of whom were suffering from moderately severe androgenization, Diane-35 (reduced to 0.035 mg ethinyl estradiol) was used as an antiandrogenically active hormonal contraceptive. From the sixth treatment cycle onward acne and seborrhea were significantly improved or already healed. In the 12th treatment cycle the treatment success rate was almost 90%. The side effects occurring with higher-dose hormonal contraceptives were reduced, cycle behavior was acceptable, and the incidence of metrorrhagia corresponded to that found with other micropills. (AUTHOR)

MJTR: Acne Vulgaris DT. Androgen Antagonists TU. Contraceptives, Oral, Hormonal TU. Cyproterone TU. Dermatitis, Seborrheic DT. Ethinyl Estradiol TU.

MNTR: Adult. Alopecia DT. Androgen Antagonists AE. Clinical Trials. Cyproterone AE. Drug Combinations AE. Drug Combinations TU. English Abstract. Ethinyl Estradiol AE. Female. Hirsutism DT. Human. Menstrual Cycle DE. Middle Age. CLINICAL TRIAL. JOURNAL ARTICLE

RNUM: 0 (Androgen Antagonists); 0 (Drug Combinations); 2098-66-0 (Cyproterone); 57-63-6 (Ethinyl Estradiol); 60528-19-0 (Diane)

GEOT: GERMANY, WEST

IDEN: ISSN: 0016-5751. JOURNAL-CODE: FK5. ENTRY-DATE: 870323. JOURNAL-SUBSET: M. IM-DATE: 8705.

ACCE: 87106660